PapersPMID:27208415
Oral trehalose supplementation improves resistance artery endothelial function in healthy middle-aged and older adults.
- findings
- 4
- compound
- 1
- endpoints
- 4
- Study, every finding
- RCT · 3 months
- Dose studied, every finding
- 100 g/day trehalose dissolved in 12 ounces of water, 12 weeks
No finding here moved its endpoint.
What did not
How to read these marks →“There were no baseline group differences in oxidized LDL, CRP, IL-6 or TNF-α and these factors did not change differentially across the intervention period in the maltose and trehalose treated groups (all P>0.1, Table 4).”
- Population
- Non-smoking men and postmenopausal women aged 50-77 years free of clinical disease, all randomized completers; comparator maltose 100 g/day, an isocaloric disaccharide
- Population
- Non-smoking men and postmenopausal women aged 50-77 years free of clinical disease, all randomized completers; comparator maltose 100 g/day, an isocaloric disaccharide
- Population
- Non-smoking men and postmenopausal women aged 50-77 years free of clinical disease, all randomized completers; comparator maltose 100 g/day, an isocaloric disaccharide
“FMD did not change differentially across the intervention in the trehalose and maltose treated groups when FMD was expressed as either percent or absolute change (both P>0.1, Figure 6).”
- Population
- Non-smoking men and postmenopausal women aged 50-77 years free of clinical disease, all randomized completers (trehalose 15, maltose 17); comparator maltose 100 g/day, an isocaloric disaccharide
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- healthy non-smoking middle-aged and older men and postmenopausal women aged 50-77 years
- Participants
- 32
- Comparator
- an active treatment
- Duration
- 84 days
- Endpoints measured
- 45